Allergy Asthma Immunol Res.  2015 Jan;7(1):88-91. 10.4168/aair.2015.7.1.88.

Superoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis

• Kim SH
• Kim SH
• Lee JH
• Lee BH
• Yoon HJ
• Shin DH
• Park SS
• Jang SB
• Park JS
• Jee YK

• KMID: 2260157
• DOI: http://doi.org/10.4168/aair.2015.7.1.88

Abstract

PURPOSE
Drug-induced liver injury (DILI) is a serious issue often leading to discontinuation of the proper regimen of antituberculosis drugs (ATD). Previous studies have suggested that antioxidant enzymes play an important role in DILI.
METHODS
We explored whether polymorphisms in superoxide dismutase genes, including Cu/Zn superoxide dismutase (SOD1), manganese superoxide dismutase (SOD2) and extracellular superoxide dismutase (SOD3) are associated with ATD-induced hepatitis. Genotype distributions of four single nucleotide polymorphisms (SNPs) in three genes (rs2070424, SOD1; rs4880, SOD2; rs2536512, and rs1799895, SOD3) were compared between 84 patients with ATD-induced hepatitis and 237 patients tolerant to ATD.
RESULTS
Intron SNP rs2070424 of SOD1 showed a significant association with ATD-induced hepatitis. The frequency of genotypes carrying minor alleles (GA or GG) was significantly higher in the case group than that of controls (P=0.019, OR=2.26, 95% CI 1.14-4.49). For the other SNPs of SOD2 and SOD3, there were no differences in genotype frequencies between ATD-induced hepatitis and ATD-tolerant controls.
CONCLUSIONS
These findings suggest that rs2070424 of SOD1 is significantly associated with ATD-induced hepatitis. This genetic variant may be a risk factor for ATD-induced hepatitis in individuals from Korea.

Keyword

Antituberculosis drugs; hepatitis; superoxide dismutase; polymorphism

MeSH Terms

Alleles
Drug-Induced Liver Injury*
Genotype
Hepatitis
Humans
Introns
Korea
Polymorphism, Single Nucleotide
Risk Factors
Superoxide Dismutase*
Superoxide Dismutase

Reference

1. American Thoracic Society. CDC. Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003; 52:1–77.

2. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174:935–952.

3. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology. 2010; 52:748–761.

4. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004; 38:Suppl 2. S44–S48.

5. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007; 3:1–8.

6. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007; 47:128–134.

7. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, Park JS, Jee YK. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinb). 2010; 90:39–43.

8. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009; 47:344–356.

9. Lucena MI, García-Martín E, Andrade RJ, Martínez C, Stephens C, Ruiz JD, Ulzurrun E, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Durán JA, De Dios AM, Guarner C, Soriano G, Borraz Y, Agundez JA. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010; 52:303–312.

10. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization;2010.

11. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167:603–662.

12. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, Song J, Kim SH, Park HS, Min KU, Jee YK. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009; 10:1767–1779.

13. Lei XG, Zhu JH, McClung JP, Aregullin M, Roneker CA. Mice deficient in Cu,Zn-superoxide dismutase are resistant to acetaminophen toxicity. Biochem J. 2006; 399:455–461.

14. Liu YM, Li XD, Guo X, Liu B, Lin AH, Rao SQ. Association between polymorphisms in SOD1 and noise-induced hearing loss in Chinese workers. Acta Otolaryngol. 2010; 130:477–486.

15. Kase BA, Northrup H, Morrison AC, Davidson CM, Goiffon AM, Fletcher JM, Ostermaier KK, Tyerman GH, Au KS. Association of copper-zinc superoxide dismutase (SOD1) and manganese superoxide dismutase (SOD2) genes with nonsyndromic myelomeningocele. Birth Defects Res A Clin Mol Teratol. 2012; 94:762–769.

16. Andrade RJ, Agúndez JA, Lucena MI, Martínez C, Cueto R, García-Martín E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab. 2009; 10:956–970.